Article
Oncology
Xiaohan Chi, Yi Wang, Chunzhao Li, Xijian Huang, Hua Gao, Yang Zhang, Nan Ji
Summary: Surgical resection of glioblastoma multiforme (GBM) is a common treatment, but its impact on immunotherapeutic outcomes is not clear. This study found that increased extent of resection (T2-EOR) was associated with worse immunotherapeutic outcomes for GBM patients receiving HSPPC-96 vaccination.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yi Wang, Chunzhao Li, Xiaohan Chi, Xijian Huang, Hua Gao, Nan Ji, Yang Zhang
Summary: Heat shock protein peptide complex 96 (HSPPC-96) is a potential therapeutic vaccine for treating glioblastoma multiforme (GBM). In this study, we found that low MxA expression was associated with longer overall survival in GBM patients receiving HSPPC-96 vaccination. However, immune cell densities and gp96 expression did not significantly impact patient outcomes. MxA expression was linked to a preexisting TCR clone (CDR3-2) but was independent of the peripheral tumor-specific immune response.
FRONTIERS IN ONCOLOGY
(2022)
Editorial Material
Oncology
Francesco Pasqualetti, Sofia Zanotti
Summary: Liau et al. recently published the findings of a Phase 3 clinical trial evaluating the efficacy of DCVax-L vaccines in patients with glioblastoma. Although the study yielded promising and significant results, some concerns were raised regarding the study design and the lengthy recruitment period.
BRITISH JOURNAL OF CANCER
(2023)
Review
Cell Biology
Binghao Zhao, Jiaming Wu, Huanzhang Li, Yuekun Wang, Yaning Wang, Hao Xing, Yu Wang, Wenbin Ma
Summary: Glioblastoma (GBM) is a highly malignant CNS tumor with a high recurrence rate. Immunotherapy has shown potential in treating recurrent GBM, but there are challenges such as the presence of the blood-brain barrier and immunosuppressive cell infiltration. Novel tumor vaccines have been designed to overcome these challenges and improve the anti-tumor immune response. This review discusses the immunological characteristics of CNS and GBM, as well as the mechanisms of each novel tumor vaccine for recurrent GBM.
CELL COMMUNICATION AND SIGNALING
(2023)
Article
Oncology
Eleonora F. Spinazzi, Michael GArgenziano, Pavan S. Upadhyayula, Matei A. Banu, Justin A. Neira, Dominique M. O. Higgins, Peter B. Wu, Brianna Pereira, Aayushi Mahajan, Nelson Humala, Osama Al-Dalahmah, Wenting Zhao, Akshay Save, BrianJ A. Gill, Deborah M. Boyett, Tamara Marie, Julia L. Furnari, Tejaswi D. Sudhakar, Sylwia A. Stopka, Michael S. Regan, Vanessa Catania, Laura Good, Stergios Zacharoulis, Meenu Behl, Petros Petridis, Sachin Jambawalikar, Akiva Mintz, Angela Lignelli, Nathalie Y. R. Agar, PeterA Sims, Mary R. Welch, Andrew B. Lassman, Fabio M. Iwamoto, Randy S. D'Amico, Jack Grinband, Peter Canoll, Jeffrey N. Bruce
Summary: The chronic CED of topotecan for recurrent glioblastoma was safely completed in all patients, showing potential as a safe and active therapy. This novel delivery approach overcomes limitations in drug delivery and treatment response assessment, providing a unique tissue-based evaluation of treatment response. Further studies are needed to determine the impact on clinical outcomes.
Review
Oncology
Stephen C. Frederico, John C. Hancock, Emily E. S. Brettschneider, Nivedita M. Ratnam, Mark R. Gilbert, Masaki Terabe
Summary: The use of immunotherapies for brain tumors has generated excitement, but challenges remain in treating GBM due to its immunologically cold nature. Strategies such as vaccine therapy combined with immune checkpoint inhibitors are being explored to overcome these challenges and enhance treatment options for patients with GBM in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Zoltan Banki, Jose Mateus, Annika Rossler, Helena Schafer, David Bante, Lydia Riepler, Alba Grifoni, Alessandro Sette, Viviana Simon, Barbara Falkensammer, Hanno Ulmer, Bianca Neurauter, Wegene Borena, Florian Krammer, Dorothee von Laer, Daniela Weiskopf, Janine Kimpel
Summary: This study demonstrates the immunogenicity and safety of heterologous AZ/BNT vaccination, which is superior to homologous AZ/AZ vaccination, encouraging further research on heterologous vaccination schedules.
Article
Oncology
Yoshitaka Narita, Yoshiko Okita, Yoshiki Arakawa
Summary: The TAS0313 vaccine demonstrated promising efficacy and acceptable safety in patients with recurrent GBM.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Medicine, Research & Experimental
Yujing Du, Zhao Chen, Ping Yan, Chunli Zhang, Xiaojiang Duan, Xueqi Chen, Meng Liu, Lei Kang, Xing Yang, Yan Fan, Jianhua Zhang, Rongfu Wang
Summary: The study identified heat shock protein 70 (HSP70) as the binding target for RRL, revealing a potential interaction between RRL and the nucleotide-binding domain (NBD) of HSP70. Clathrin-dependent endocytosis and macropinocytosis were suggested as vital internalization mechanisms of RRL. In vivo, Tc-99m-MAG3-RRL demonstrated satisfactory tumor accumulation and targeting, providing a promising probe for visualizing overexpressed HSP70 tumor sections.
MOLECULAR PHARMACEUTICS
(2021)
Article
Biochemistry & Molecular Biology
Zifei Han, Shelli R. McAlpine, Robert Chapman
Summary: This study demonstrates the successful delivery of inhibitors to block the interaction between Hsp70 and HOP using polymer nanogels. The results show the effectiveness of these inhibitors in inhibiting Hsp70 and inducing cancer cell death.
BIOORGANIC CHEMISTRY
(2022)
Review
Immunology
Fenge Li, Huancheng Wu, Xueming Du, Yimo Sun, Barbara Nassif Rausseo, Amjad Talukder, Arjun Katailiha, Lama Elzohary, Yupeng Wang, Zhiyu Wang, Gregory Lizee
Summary: The EGFR gene is frequently overexpressed and mutated in various solid tumors, and peptide vaccines targeting mutated EGFR have shown promising clinical efficacy and safety profiles.
Article
Pharmacology & Pharmacy
Evren Onay Ucar, Aslihan Sengelen, Elif Mertoglu Kamali
Summary: The study reveals that heat shock response (HSR) is closely related to therapeutic resistance of gliomas. Resveratrol (RSV) shows potential as an experimental agent for glioblastoma (GB) therapy, but the role of heat shock proteins (Hsps) in RSV efficacy remains unclear. The findings suggest that silencing Hsp27, Hsp60, Hsp70, and Hsp90 makes glioma cells more sensitive to RSV treatment, making these Hsps potential therapeutic targets for GB treatment.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Oncology
Hamed Hosseinalizadeh, Mohammad Rahmati, Ammar Ebrahimi, Roddy S. O'Connor
Summary: Glioblastoma (GBM), the most common and deadly type of central nervous system malignancy in adults, has a poor prognosis despite current treatments. Vaccination with tumor vaccines, either as monotherapy or in combination with other immunotherapies, is being increasingly discussed as a potential treatment approach. This article reviews the use of peptide, genetic, and cell-based vaccines in active immunotherapy for GBM and highlights the need for further research to improve their efficacy.
MOLECULAR CANCER THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Zhengyan Feng, Xiangqiang Zhan, Jia Pang, Xue Liu, Huiming Zhang, Zhaobo Lang, Jian-Kang Zhu
Summary: In this study, a novel Hsp20 protein called RDS1 was identified as a cellular factor involved in the stable epigenetic silencing of a heavily methylated transgene in Arabidopsis. RDS1, along with other Hsp20, Hsp40, and Hsp70 proteins, forms a complex that regulates the silencing state of genomic regions with DNA methylation. Loss-of-function mutations in RDS1, RDS2, MBD5, and MBD6 lead to the release of transgene silencing without altering DNA methylation levels.
JOURNAL OF INTEGRATIVE PLANT BIOLOGY
(2021)
Article
Oncology
Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang Yao
Summary: This article presents the efficacy and safety of Anlotinib in recurrent or metastatic primary malignant bone tumors. The results showed that Anlotinib had significant effects on progression-free survival (PFS) and manageable adverse events (AEs).
FRONTIERS IN ONCOLOGY
(2022)
